C017 Dermatology Review: Skin Cancer, Surgical, and Cosmetic
DESCRIPTION
In the surgical portion of this course, we will analyze the value added in the designation of a chronic disease for the treatment of the patient population with multiple keratinocyte carcinomas, develop an approach to the use of chemoprophylaxis in patients with multiple squamous cell carcinomas, describe the evidence for Mohs for melanoma and summarize the surgical management of dysplastic nevi and AIMP.
In the cosmetic portion of this course, we will discuss new laser and energy devices; evaluate and compare neuromodulators currently available on the market, outline an approach to the treatment of rhinophyma, and learn how to best utilize injectables as biostimulators.
Finally, we will end with a roundtable discussion-based format on optimizing models for the use of mid-levels in dermatologic practice.
LEARNING OBJECTIVES
Analyze the value added in the designation of a chronic disease for the treatment of the patient population with multiple keratinocyte carcinomas; develop an approach to the use of chemoprophylaxis in patients with multiple squamous cell carcinomas; describe the evidence for Mohs for melanoma; summarize the surgical management of dysplastic nevi and AIMP.
Discuss new laser and energy devices; evaluate and compare neuromodulators currently available on the market, outline an approach to the treatment of rhinophyma, and learn how to best utilize injectables as biostimulators.
Discuss optimal models for the use of mid-levels in practice.
SCHEDULE
1:00 PM
Surgical management of dysplastic nevi and AIMP
Natalie Spaccarelli, MD
1:15 PM
Value added in consideration of NMSC as chronic disease
Adam Vincent Sutton, MD, MBA, FAAD
1:30 PM
When to use chemoprophylaxis in patients with multiple SCC
Joi B. Carter, MD, FAAD
1:45 PM
Update: The evidence for Mohs for melanoma
Naomi Lawrence, MD, FAAD
2:00 PM
Discussion
Naomi Lawrence, MD, FAAD, Joi B. Carter, MD, FAAD, Natalie Spaccarelli, MD, Adam Vincent Sutton, MD, MBA, FAAD
2:07 PM
Use of filler as a biostimulator
Kimberly J. Butterwick, MD, FAAD
2:22 PM
What is new in laser and energy based devices?"
Omar Ibrahimi, MD, PhD, FAAD
2:37 PM
Comparison of Toxins available and rationale for using different toxins
Deirdre Hooper, MD, FAAD
2:52 PM
Update on the treatment of Rhinophyma
Suzanne L Kilmer, MD, FAAD
3:07 PM
Discussion
Kimberly J. Butterwick, MD, FAAD, Deirdre Hooper, MD, FAAD, Omar Ibrahimi, MD, PhD, FAAD, Suzanne L Kilmer, MD, FAAD
3:15 PM
Optimizing the model for use of midlevel providers
Allison Therese Vidimos, MD, RPh, FAAD
3:30 PM
Optimizing the model for use of midlevel providers
Allison K. Arthur, MD, FAAD
3:45 PM
Discussion
Naomi Lawrence, MD, FAAD, Allison K. Arthur, MD, FAAD, Allison Therese Vidimos, MD, RPh, FAAD
DIRECTOR
Naomi Lawrence, MD, FAAD
SPEAKERS
Allison K. Arthur, MD, FAAD
Kimberly J. Butterwick, MD, FAAD
Joi B. Carter, MD, FAAD
Deirdre Hooper, MD, FAAD
Omar Ibrahimi, MD, PhD, FAAD
Suzanne L Kilmer, MD, FAAD
Natalie Spaccarelli, MD
Adam Vincent Sutton, MD, MBA, FAAD
Allison Therese Vidimos, MD, RPh, FAAD
DISCLOSURES
Allison K. Arthur, MD, FAAD
Sand Lake Dermatology Center – Other(Salary);
Kimberly J. Butterwick, MD, FAAD
Allergan, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Evolus, Inc. – Advisory Board(Honoraria); Galderma – Advisory Board(Honoraria); Merz Pharmaceuticals, LLC – Advisory Board(Honoraria); Neutrogena Corporation – Advisory Board(Honoraria); Rapalogix Health – Stockholder Private Company(Stock); Revance Therapeutics, Inc. – Advisory Board(Honoraria);
Joi B. Carter, MD, FAAD
No financial relationships exist with ineligible companies.
Deirdre Hooper, MD, FAAD
Allergan Aesthetics – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees); Cara Therapeutics – Investigator(Fees); Cassiopea S.p.A. – Investigator(Fees); Dermavent – Investigator(Fees); Evommune – Investigator(Fees); Galderma Laboratories, L.P. – Investigator(Fees); Galderma Laboratories, LP – Advisory Board(Fees), Consultant (1099 relationship)(Fees); HMP Education – Speaker/Faculty Education(Fees); Incyte Corporation – Investigator(Fees); Leo Pharma Inc – Investigator(Fees); Parallel Health – Consultant (1099 relationship)(Fees); Revance Therapeutics, Inc. – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Speaker(Honoraria); Revision Skincare – Advisory Board(Fees), Consultant (1099 relationship)(Fees); Rion Aesthetics – Investigator(Fees); Sanofi – Investigator(Fees); SCALE (Symposium for Cosmetic Advances and Laser Education) – Speaker/Faculty Education(Honoraria); Sun Pharmaceutical Industries Ltd. – Investigator(Fees); Supergoop! – Stockholder Public Company(Stock Options); Technoderma Medicines – Investigator(Fees); TruElastin – Consultant (1099 relationship)(Fees); UCB – Investigator(Fees); VYNE Therapeutics – Investigator(Fees);
Omar Ibrahimi, MD, PhD, FAAD
Accure, Inc – Advisory Board(No Compensation Received); Allergan, Inc – Advisory Board(Honoraria); AVAVA, LLC – Investigator(Grants/Research Funding); Cynosure-Lutronic – Consultant (1099 relationship)(Honoraria); Cytrellis Biosystems, Inc – Advisory Board(Honoraria); Quthero, Inc – Consultant (1099 relationship)(Honoraria); Unilever – Stockholder(Stock);
Suzanne L Kilmer, MD, FAAD
Acclaro Medical – Advisory Board(Stock Options); Accure Acne Inc. – Advisory Board(Stock), Investigator(Grants/Research Funding); Allergan Aesthetics – Advisory Board(Honoraria), Investigator(Grants/Research Funding); AVAVA, Inc. – Investigator(No Compensation Received); AVAVA, LLC – Stockholder Private Company(No Compensation Received); Beiersdorf, Inc. – Advisory Board(Honoraria); BellaMia Technologies Inc. – Advisory Board(Honoraria), Advisory Board(Stock Options); BTL Industries, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Caliway Biopharmaceuticals Co., Ltd – Advisory Board(Honoraria); Cynosure-Lutronic – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Cytrellis Biosystems, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Stockholder Private Company(Stock); Engage Technologies – Advisory Board(Stock), Stockholder Private Company(Stock); Galderma – Advisory Board(No Compensation Received); L'Oreal – Investigator(Grants/Research Funding); Lumenis – Advisory Board(Honoraria), Investigator(No Compensation Received); Revance Therapeutics, Inc. – Advisory Board(Stock); Sofwave – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Solta Medical – Investigator(Grants/Research Funding); Solta Medical Inc – Advisory Board(Honoraria);
Naomi Lawrence, MD, FAAD
No financial relationships exist with ineligible companies.
Natalie Spaccarelli, MD
No financial relationships exist with ineligible companies.
Adam Vincent Sutton, MD, MBA, FAAD
No financial relationships exist with ineligible companies.
Allison Therese Vidimos, MD, RPh, FAAD
Castle Biosciences – Investigator(Grants/Research Funding); Inhibitor Therapeutics – Advisory Board(No Compensation Received); Regeneron – Data Safety Monitoring Board(Fees); SolGel Technologies – Investigator(Grants/Research Funding); UpToDate, Inc – Other(Honoraria);